www.observia-group.com - Observia is a European Healthtech company that aims to improve the lives of chronic patients and ease the daily lives of healthcare professionals by building next-generation digital support. At Observia, we collaborate with all stakeholders from the healthcare environment. We deeply believe that by understanding patients better and personalizing their support we can change the way the healthcare system performs, making it more empathetic and more efficient. ====================================================================== Small Talk Big Issue is a mini web-series of interviews focusing on how to revolutionize healthcare and build next generation digital patient support. In each video, Kevin Dolgin interviews an important guest from the healthcare world and asks him or her three or four questions related to the future of patient support. The guests are researchers, public payors, healthcare professionals, patient representatives and industry representatives who have accepted to share with us insights from their work, their successes, their failures and their concerns. We hope you like it, and even better, that you can find inspiration and food for thought. ====================================================================== Kevin asked Paul Simms four questions ➀ Will it be pharma who takes the lead in the digital patient support revolution, or somebody else? [0:52] ➁ What is stopping pharma from taking the lead? [4:42] ➂ Do you think there is a future for collaboration across pharma companies to face the GAFA threat? [9:24] ➃ Is there something that you experienced that made you realize that patient-centricity is the way to go and the future of pharma? [12:50] ====================================================================== BIO Kevin Dolgin is one of the founders of Observia, as well as an associate professor at Paris I University (Panthéon-Sorbonne). Prior to Observia, he created Areks, which became part of IMS Health in 2005, where Kevin remained in a thought leadership role until 2010. He has been widely published in both business and scientific publications and has been a speaker at numerous international conferences. He received a BA from Fordham University (USA), an MBA from INSEAD (France) and a Master of Research (MRes) at the Sorbonne, in Paris. https://www.linkedin.com/in/kevin-dolgin-2289ba4/ Paul Simms’ company PS∆ specialises in identifying trends, scoping new business models and designing new services to modernize and reimagine the pharmaceutical industry. Paul can often be found challenging industry executives, proposing new ways forward and presenting to anyone who will listen. Previously Paul spent 17 years building eyeforpharma from zero into the industry’s largest and most influential events company, creating a platform for leaders and innovators that raised standards, empowered patients and started movements. The business was acquired by Reuters in 2019. https://www.linkedin.com/in/psimms/ ====================================================================== Did you like what you heard? You want to follow our news? Join us on our social media and visit our website Linkedin - linkedin.com/company/observia Youtube STBI page - https://bit.ly/3lKwVI3 Youtube Observia's page https://bit.ly/2Z25foe Twitter https://twitter.com/Observia_Esante"

• published: 28 Sep 2020
• views: 163